Currently, the analyst consensus on Ovintiv is a Strong Buy with an average price target of $53.93, representing a 24.92% upside. In a report released today, Barclays also maintained a Buy rating on ...
Crispr has already secured a historic first approval for a CRISPR/Cas9 drug and has several more potential blockbuster ...
RBC Capital analyst Gregory Pardy maintained a Hold rating on Ovintiv (OVV – Research Report) on November 8 and set a price target of ...
AbbVie Inc. shares fell the most in three years after two mid-stage trials of its drug to treat schizophrenia failed to meet ...
Price Action: AbbVie stock is down 10.6% at $178.32, while Bristol Myers Squibb stock is up 13% at $61.20 during the ...
Corteva's Q3 results showed weak growth in Latin America, but benefits from raw material cost deflation. Read why I reiterate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback